RT Journal Article
SR Electronic
T1 ERAP1, ERAP2, and two copies of HLA-Aw19 alleles increase the risk for Birdshot Chorioretinopathy in HLA-A29 carriers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.02.21259921
DO 10.1101/2021.07.02.21259921
A1 Sahar Gelfman
A1 Dominique Monnet
A1 Ann J. Ligocki
A1 Thierry Tabary
A1 Arden Moscati
A1 Xiaodong Bai
A1 Jan Freudenberg
A1 Blerta Cooper
A1 Jack A. Kosmicki
A1 Sarah Wolf
A1 Regeneron Genetics Center
A1 Manuel A. R. Ferreira
A1 John Overton
A1 Jonathan Weyne
A1 Eli A. Stahl
A1 Aris Baras
A1 Carmelo Romano
A1 Jacques H. M. Cohen
A1 Giovanni Coppola
A1 Antoine Brézin
YR 2021
UL http://medrxiv.org/content/early/2021/07/05/2021.07.02.21259921.abstract
AB Purpose Birdshot Chorioretinopathy (BSCR) is strongly associated with HLA-A29. This study was designed to elucidate the genetic modifiers of BSCR in HLA-A29 carriers.Methods We sequenced the largest BSCR cohort to date, including 286 cases and 108 HLA-A29 positive controls to perform genome wide common and rare variant associations. We further typed the HLA alleles of cases and 45,386 HLA-A29 controls of European ancestry to identify HLA alleles that associate with BSCR risk.Results Carrying a second allele that belongs to the HLA-Aw19 broad antigen family (including HLA-A29, A30, A31, and A33) increases the risk for BSCR (OR=4.44, p=2.2e-03). This result was validated by comparing allele frequencies to large HLA-A29-controlled cohorts (n=45,386, OR>2.5, p<1.3e-06). We also confirm that ERAP1 and ERAP2 haplotypes modulate the risk for disease within our HLA-A29 controlled cohort. A meta-analysis with an independent dataset confirmed that ERAP1 and ERAP2 haplotypes modulate the risk for disease at a genome-wide significant level: ERAP1-rs27432 (OR 2.46; 95% CI 1.85-3.26; p=4.07e-10), an eQTL decreasing ERAP1 expression, and ERAP2-rs10044354 (OR 1.95; 95% CI 1.55-2.44; p=6.2e-09), an eQTL increasing ERAP2 expression. Furthermore, ERAP2-rs2248374 that disrupts ERAP2 expression is protective (OR 0.56; 95% CI [0.45-0.70]; p=2.39e-07). BSCR risk is additively increased when combining ERAP1/ERAP2 risk genotypes with two copies of HLA-Aw19 alleles (OR 13.53; 95% CI 3.79-54.77, p=1.17e-05).Conclusions The genetic factors increasing BSCR risk demonstrate a pattern of increased processing, as well as increased presentation of ERAP2 specific peptides. This suggests a mechanism in which exceeding a peptide presentation threshold activates the immune response in choroids of A29 carriers.Competing Interest StatementS.G, A.J.L, A.M, X.B, J.F, B.C, J.A.K, S.W, M.F, J.O, J.W, E.A.S, A.B, C.R and G.C are current employees and/or stockholders of Regeneron Genetics Center or Regeneron Pharmaceuticals. All other authors declare no conflict of interest.Funding StatementThis research received funding from Regeneron Pharmaceuticals. The non-profit foundation Association d'Ophtalmologie de Cochin funded part of the banking of patient samples.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Signed informed consent documentation was obtained from all participants, and all research adhered to the tenets set forth in the Declaration of Helsinki. All study-related data acquisitions were approved by the Paris Cochin institutional review board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this manuscript are reported in the main text, in the figures, or in the supplementary materials.Aw19HLA-Aw’19 broad antigen serotype groupBSCRBirdshot ChorioretinopathyGHSGeisinger Health SystemMAFminor allele frequencyUKBUK Biobank